Cullinan Therapeutics (Cullinan Therapeutics) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Cullinan Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.44 Mil. Cullinan Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.15 Mil. Cullinan Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $453.70 Mil. Cullinan Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cullinan Therapeutics's Debt-to-Equity or its related term are showing as below:

CGEM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of Cullinan Therapeutics was 0.01. The lowest was 0.01. And the median was 0.01.

CGEM's Debt-to-Equity is ranked better than
99.91% of 1073 companies
in the Biotechnology industry
Industry Median: 0.14 vs CGEM: 0.01

Cullinan Therapeutics Debt-to-Equity Historical Data

The historical data trend for Cullinan Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

Cullinan Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity															0.01	0.01	0.01	0.01	0.01

Competitive Comparison

For the Biotechnology subindustry, Cullinan Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cullinan Therapeutics Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's Debt-to-Equity falls into.

Cullinan Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cullinan Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.44	+	2.15)	/	453.703
	=	0.01

Cullinan Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.44	+	2.15)	/	453.703
	=	0.01

Cullinan Therapeutics (NAS:CGEM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cullinan Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics (Cullinan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, Suite 520, Cambridge, MA, USA, 02142

Website

https://www.cullinanoncology.com

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Executives

Nadim Ahmed	director, officer: President and CEO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer	officer: Chief Legal Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson	officer: See Remarks	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio	officer: Chief Financial Officer	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan	director	C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2	10 percent owner	74 GRAND RUE, LUXEMBURG N4 L-1660
Savill Corrine	officer: Acting Chief Business Officer	C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
F2 Bioscience I 2017 Ltd	10 percent owner	8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin	director	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104